Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …

Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …

Sonodynamic therapy (SDT) exhibits high tissue penetration and negligible radiation
damage to normal tissues, and thus emerges as a promising cancer therapeutic modality for …

Following its discovery more than 30 years ago, the enhanced permeability and retention
(EPR) effect has become the guiding principle for cancer nanomedicine development. Over …

Glioblastoma (GBM) is an intractable malignancy with high recurrence and mortality.
Combinatorial therapy based on temozolomide (TMZ) and cisplatin (CDDP) shows …

Owing to the unique advantages of photoacoustic imaging (PAI) and photothermal therapy
(PTT) conducted over the near‐infrared‐II (NIR‐II) window, the development of high …

Glioblastoma (GBM) is a central nervous system tumor with poor prognosis due to the rapid
development of resistance to mono chemotherapy and poor brain targeted delivery …

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor
with a high mortality rate. Immunotherapy has achieved promising clinical results in multiple …

Existing drug delivery methods have not led to a significant increase in survival for patients
with malignant primary brain tumors. While the combination of conventional therapies …

Simple Summary Glioblastoma multiforme is one of the hardest-to-treat brain tumors, often
resistant to conventional treatments such as chemotherapy and radiation therapy. Despite …